

TOM DAVIS, VIRGINIA,  
CHAIRMAN

DAN BURTON, INDIANA  
CHRISTOPHER SHAYS, CONNECTICUT  
ILEANA ROS-LEHTINEN, FLORIDA  
JOHN M. McHUGH, NEW YORK  
JOHN L. MICA, FLORIDA  
MARK E. SOUDER, INDIANA  
STEVEN C. LATOURETTE, OHIO  
DOUG OSE, CALIFORNIA  
RON LEWIS, KENTUCKY  
JO ANN DAVIS, VIRGINIA  
TODD RUSSELL PLATTS, PENNSYLVANIA  
CHRIS CANNON, UTAH  
ADAM H. PUTNAM, FLORIDA  
EDWARD L. SCHROCK, VIRGINIA  
JOHN J. DUNCAN, JR., TENNESSEE  
NATHAN DEAL, GEORGIA  
CANDICE MILLER, MICHIGAN  
TIM MURPHY, PENNSYLVANIA  
MICHAEL R. TURNER, OHIO  
JOHN R. CARTER, TEXAS  
MARSHA BLACKBURN, TENNESSEE  
PATRICK J. TIBERI, OHIO  
KATHERINE HARRIS, FLORIDA

ONE HUNDRED EIGHTH CONGRESS

# Congress of the United States

## House of Representatives

COMMITTEE ON GOVERNMENT REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074  
FACSIMILE (202) 225-3974  
MINORITY (202) 225-5051  
TTY (202) 225-6852

[www.house.gov/reform](http://www.house.gov/reform)

HENRY A. WAXMAN, CALIFORNIA,  
RANKING MINORITY MEMBER

TOM LANTOS, CALIFORNIA  
MAJOR R. OWENS, NEW YORK  
EDOLPHUS TOWNS, NEW YORK  
PAUL E. KANJORSKI, PENNSYLVANIA  
CAROLYN B. MALONEY, NEW YORK  
ELIJAH E. CUMMINGS, MARYLAND  
DENNIS J. KUCINICH, OHIO  
DANNY K. DAVIS, ILLINOIS  
JOHN F. TIERNEY, MASSACHUSETTS  
WM. LACY CLAY, MISSOURI  
DIANE E. WATSON, CALIFORNIA  
STEPHEN F. LYNCH, MASSACHUSETTS  
CHRIS VAN HOLLEN, MARYLAND  
LINDA T. SANCHEZ, CALIFORNIA  
C.A. DUTCH RUPPERSBERGER,  
MARYLAND  
ELEANOR HOLMES NORTON,  
DISTRICT OF COLUMBIA  
JIM COOPER, TENNESSEE  
BETTY McCOLLUM, MINNESOTA

BERNARD SANDERS, VERMONT,  
INDEPENDENT

October 13, 2004

Lester Crawford, D.V.M., Ph.D.  
Acting Commissioner  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

Dear Dr. Crawford:

On October 5, 2004, the British government's Medicines and Healthcare Products Regulatory Agency (MHRA) suspended the Chiron Corporation's influenza vaccine-manufacturing license effective immediately for three months because of manufacturing problems. The suspension prohibits Chiron from manufacturing, shipping, or marketing its Fluvirin vaccine. Chiron had planned to provide the U.S. between 46-48 million flu shots this year, almost half of the nation's supply. Officials from the Center for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and Chiron claim to have been informed of MHRA's decision on October 5, 2004. However, recent news reports raise questions about whether CDC and FDA officials had knowledge of the impending suspension of Chiron's license as early as September 13, 2004.

On October 8, 2004, the Committee held a hearing to examine the factors contributing to the influenza vaccine shortage. As a result of information obtained during the hearing and the recent news articles, the Committee is investigating the circumstances surrounding Chiron's suspension and whether any warning signs existed to indicate to CDC and/or FDA the possibility of a license suspension. Therefore, please produce the following documents to the Committee by October 20, 2004:

1. A copy of the Form 483 and the Establishment Inspection Report from FDA's June 2003 inspection of the Chiron's Liverpool Fluvirin facility;
2. Any and all copies of correspondence, meeting notes, and electronic communications between Chiron and FDA with regard to the deficiencies identified during the June 2003 inspection;

Dr. Lester Crawford  
October 13, 2004  
Page 2

3. Any and all copies of correspondence, meeting notes, records of telephone calls, and electronic communications between Chiron and FDA subsequent to the company's August 25, 2004 announcement of contamination;
4. Any and all copies of records regarding communications between FDA and MHRA concerning the possibility of suspending Chiron's license to manufacture Fluvirin at the Liverpool facility; and
5. A timeline from August 1, 2004 to October 5, 2004 of actions taken by FDA, alone or in conjunction with Chiron, to remedy the problem of contamination at Chiron's Liverpool Fluvirin facility. This timeline should include, but not be limited to:
  - a. the date FDA was first notified of the contamination, by Chiron and/or MHRA; and
  - b. the date FDA was first notified of the possibility of Chiron's license suspension, by Chiron and/or MHRA.

Additionally, the Committee requests you make available for interviews those FDA employees who were responsible for inspections of Chiron's Liverpool Fluvirin facility and communications with the company from the June 2003 inspection to the present.

Thank you for your timely attention to this matter. If you have any questions about this request, please contact Susie Schulte, Majority Professional Staff, at (202) 225-5074, or Sarah Despres, Minority Professional Staff, at (202) 225-5420.

Sincerely,



Tom Davis  
Chairman



Henry A. Waxman  
Ranking Minority Member